ASN
ATXS

Advisory Services Network’s Astria Therapeutics ATXS Stock Holding History

Advisory Services Network’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-41
Closed -$315 – 1605
2023
Q4 		$315 Buy
+41
New +$227 ﹤0.01% 3681
2023
Q2 		– Sell
-41
Closed -$545 – 1588
2023
Q1 		$545 Buy
+41
New +$554 ﹤0.01% 3724

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advisory Services Network's ATXS Position: Q1 2024 in Review

Advisory Services Network sold out of Astria Therapeutics (ATXS) in Q1 2024, closing a stake of 41 shares — an estimated $315 sold.

Advisory Services Network first reported a position in ATXS in Q1 2023 and held it in 2 quarters. The position peaked at $545 in Q1 2023. 102 funds tracked by Wall St. Rank hold ATXS as of Q1 2024.

  • Advisory Services Network reported no remaining Astria Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Advisory Services Network sold 41 Astria Therapeutics shares in Q1 2024, an estimated $315.
  • Advisory Services Network first reported a position in Astria Therapeutics in Q1 2023 and held it in 2 quarters.
  • Advisory Services Network's Astria Therapeutics position peaked at $545 in Q1 2023.
  • 102 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2024.

Based on Advisory Services Network's 13F filing for Q1 2024, filed 6 May 2024.